Molecular Partners leverages DARPins for oncology treatments, but Novartis' exit raises concerns. Click here to read why ...

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027IND filing and initial clinica ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development ... both companies to fuel a broad and ...

Its pipeline includes EOS-448 ... and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered ...

France’s Orano has launched the serial production of ten 30B-10 cylinders designed to transport uranium hexafluoride (UF6) ...

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear ...

Orano, a French state-owned nuclear fuel company, is considering selling its uranium assets in Niger following a collapse in relations with the country's military-led government, reported the ...

In January, we expanded our strategic radiotherapy partnership with Orano Med and are continuing to advance the lead program, MP0712, towards a first-in-human trial. With the data package of ...

Additionally, they presented initial preclinical data for a second Radio-DARPin targeting mesothelin (MSLN), also co-developed with Orano Med, and further proof-of-concept data on a logic-gated ...